AmealPeptide® (Casein Lactotripeptides VPP and IPP)

Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

AmealPeptide® is a casein-derived ingredient supplying the lactotripeptides VPP (valyl-prolyl-proline) and IPP (isoleucyl-prolyl-proline), developed from a fermentation process pioneered with the Calpis fermented-milk tradition. These small milk peptides act like a gentle, natural ACE inhibitor and are studied for supporting healthy blood pressure.

Studied Dose Around 3 to 4 mg of combined VPP and IPP per day.
Active Compound Casein-derived lactotripeptides valyl-prolyl-proline (VPP) and isoleucyl-prolyl-proline (IPP).

Benefits

Healthy blood pressure

A meta-analysis of randomized trials found the lactotripeptides VPP and IPP produced a modest reduction in systolic blood pressure, supporting their blood-pressure positioning.

Arterial elasticity

By gently inhibiting the ACE enzyme, the peptides support relaxed, flexible blood vessels.

Natural ACE-inhibitor action

The peptides offer a food-derived way to support the body's blood-pressure regulation, with a strong safety record.

Mechanism of action

1

ACE inhibition

VPP and IPP inhibit angiotensin-converting enzyme (ACE), reducing formation of the vessel-constricting hormone angiotensin II and supporting lower blood pressure.

2

Vascular support

Lower angiotensin II activity helps blood vessels stay relaxed, supporting healthy circulation.

Clinical trials

1
Lactotripeptides and Blood Pressure — Meta-Analysis
PubMed

Meta-analysis of randomized controlled trials of the lactotripeptides IPP and VPP on systolic blood pressure in European subjects. (Cicero et al. 2013, American Journal of Hypertension)

Adults across multiple RCTs.

The lactotripeptides produced a modest but statistically significant reduction in systolic blood pressure versus placebo.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated — derived from milk protein.
Mild digestive upset is occasionally reported.
Avoid if you have a milk-protein allergy.

Important Drug interactions

Blood pressure medication — possible additive effect; monitor.
ACE inhibitors — theoretical additive effect; tell your doctor.
Tell your doctor if you take cardiovascular medication.

Frequently asked questions about AmealPeptide® (Casein Lactotripeptides VPP and IPP)

What is AmealPeptide?

AmealPeptide® is a casein-derived ingredient supplying the lactotripeptides VPP (valyl-prolyl-proline) and IPP (isoleucyl-prolyl-proline), developed from a fermentation process pioneered with the Calpis fermented-milk tradition.

What is AmealPeptide used for?

AmealPeptide is researched primarily for Cardiovascular. A meta-analysis of randomized trials found the lactotripeptides VPP and IPP produced a modest reduction in systolic blood pressure, supporting their blood-pressure positioning.

What is the recommended dosage of AmealPeptide?

The clinically studied dose is Around 3 to 4 mg of combined VPP and IPP per day. Always follow the product label and check with a healthcare provider for personal advice.

Is AmealPeptide safe, and does it have side effects?

For most healthy adults, AmealPeptide is well tolerated at studied doses. Reported effects can include: Generally well-tolerated — derived from milk protein. Mild digestive upset is occasionally reported. It may also interact with some medications. AmealPeptide is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AmealPeptide interact with any medications?

Possible interactions include: Blood pressure medication — possible additive effect; monitor. ACE inhibitors — theoretical additive effect; tell your doctor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AmealPeptide?

NutraSmarts rates the evidence for AmealPeptide as Moderate (3 out of 5). It is backed by 1 clinical trial and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Cicero AF, Aubin F, Azais-Braesco V, et al. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013;26(3):442-9..PubMedUsed to support: Meta-analysis supporting modest blood-pressure benefit of lactotripeptides.